<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-0108</journal-id>
<journal-title><![CDATA[Revista Española de Enfermedades Digestivas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. esp. enferm. dig.]]></abbrev-journal-title>
<issn>1130-0108</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Patología Digestiva]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-01082007001100005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Daño hepático y enfermedad celíaca]]></article-title>
<article-title xml:lang="en"><![CDATA[Liver damage and celiac disease]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cantarero Vallejo]]></surname>
<given-names><![CDATA[M. D.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Camarero]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Menchén]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pajares Díaz]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lo Iacono]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Centro de Salud de Illescas Consulta de Pediatría de AP ]]></institution>
<addr-line><![CDATA[Toledo ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Hospital General Universitario Gregorio Marañón y Ciberehd Servicio de Medicina del Aparato Digestivo ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>11</month>
<year>2007</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>11</month>
<year>2007</year>
</pub-date>
<volume>99</volume>
<numero>11</numero>
<fpage>648</fpage>
<lpage>652</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-01082007001100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-01082007001100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-01082007001100005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[La enfermedad celiaca (EC) es una causa importante de elevación de transaminasas: entre un 5 y un 10% de los pacientes con elevación crónica, criptogénica, de las transaminasas presentan EC y, al contrario, la EC puede estar asociada a diferentes enfermedades hepáticas. En efecto, un amplio abanico de patología hepática puede asociarse a EC, tanto en niños como en adultos, que pueden resumirse en: a) daño hepático mínimo caracterizado por la ausencia de síntomas o signos clínicos asociables a una enfermedad hepática crónica y con cambios histológicos no específicos que desaparecen después de la introducción de una dieta sin gluten; b) hepatopatías de etiología autoinmune, incluyendo la hepatitis autoinmune, la colangitis esclerosante primaria y la cirrosis biliar primaria, en las que la respectiva evolución no está influenciada por la introducción de dieta sin gluten; y c) insuficiencia hepática grave y cirrosis hepática criptogénica descompensada, potencialmente tratables con la dieta sin gluten. Todas estas patologías están condicionadas por diferentes factores individuales y por una predisposición genética. La progresión y la reversibilidad del daño hepático en los diferentes cuadros patológicos, pueden estar condicionadas por la exposición al gluten y la edad, precoz o tardía, en la cual ha sido introducido en la dieta. Hay suficiente evidencia clínica para recomendar un atento cribado cruzado tanto para el diagnóstico del daño hepático asintomático en los pacientes con EC como para el diagnóstico de la EC en los pacientes con daño hepático criptogénico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Celiac disease (CD) is an important cause of serum aminotransferase elevation: between 5 and 10% of patients with persistent and cryptogenetic transaminase elevation may have CD. In fact, a wide spectrum of liver injuries in children and adults may be related to CD, particularly: a) mild parenchymal damage characterized by absence of any clinical signs or symptoms suggesting chronic liver disease, and by non-specific histological changes reversible on a gluten-free diet; b) chronic liver damage with autoimmune etiology, including autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis, which may be associated with CD but are generally unaffected by gluten withdrawal; and c) severe liver failure and decompensated cryptogenetic liver cirrhosis, potentially treatable with a gluten-free diet. Such different types of liver injuries may represent one same disorder where individual factors, such as genetic predisposition, precocity, and duration of exposure to gluten may influence reversibility of liver damage. A rigorous cross-checking for asymptomatic liver damage in CD individuals and, conversely, for CD in any cryptogenic liver disorder, including end-stage liver failure, is recommended.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedad celiaca]]></kwd>
<kwd lng="es"><![CDATA[Hepatopatía]]></kwd>
<kwd lng="es"><![CDATA[Anti-tTG]]></kwd>
<kwd lng="es"><![CDATA[Transaminasas]]></kwd>
<kwd lng="en"><![CDATA[Celiac disease]]></kwd>
<kwd lng="en"><![CDATA[Liver disease]]></kwd>
<kwd lng="en"><![CDATA[Anti-tTG]]></kwd>
<kwd lng="en"><![CDATA[Transaminase]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[   <B><FONT FACE="Verdana" SIZE=2>    <P ALIGN="RIGHT"><A NAME="top"></A>PUNTO DE VISTA</P> </B></FONT>    <P>&nbsp;</P> <B><FONT FACE="Verdana" SIZE=4>    <P>Da&ntilde;o hep&aacute;tico y enfermedad cel&iacute;aca</P>     <P>Liver damage and celiac disease</P> </B></FONT>    <P>&nbsp;</P>     <P>&nbsp;</P> <B><FONT FACE="Verdana" SIZE=2>    <P>M. D. Cantarero Vallejo, J. G&oacute;mez Camarero<SUP>1</SUP>, L. Mench&eacute;n<SUP>1</SUP>, J. A. Pajares D&iacute;az<SUP>1</SUP> y O. Lo Iacono<SUP>1</P> </B></SUP>    <P>Consulta de Pediatr&iacute;a de AP. Centro de Salud de Illescas. Toledo. <SUP>1</SUP>Servicio de Medicina del Aparato Digestivo. Hospital General Universitario Gregorio Mara&ntilde;&oacute;n y Ciberehd. Madrid</P> </FONT>    <P><a HREF="#back"><FONT FACE="Verdana" SIZE=2>Direcci&oacute;n para correspondencia</FONT></a></P>     ]]></body>
<body><![CDATA[<P>&nbsp;</P>     <P>&nbsp;</P>     <P><HR SIZE=0> <B><FONT FACE="Verdana" SIZE=2>    <P>RESUMEN</P> </B>    <P>La enfermedad celiaca (EC) es una causa importante de elevaci&oacute;n de transaminasas: entre un 5 y un 10% de los pacientes con elevaci&oacute;n cr&oacute;nica, criptog&eacute;nica, de las transaminasas presentan EC y, al contrario, la EC puede estar asociada a diferentes enfermedades hep&aacute;ticas. En efecto, un amplio abanico de patolog&iacute;a hep&aacute;tica puede asociarse a EC, tanto en ni&ntilde;os como en adultos, que pueden resumirse en: a) da&ntilde;o hep&aacute;tico m&iacute;nimo caracterizado por la ausencia de s&iacute;ntomas o signos cl&iacute;nicos asociables a una enfermedad hep&aacute;tica cr&oacute;nica y con cambios histol&oacute;gicos no espec&iacute;ficos que desaparecen despu&eacute;s de la introducci&oacute;n de una dieta sin gluten; b) hepatopat&iacute;as de etiolog&iacute;a autoinmune, incluyendo la hepatitis autoinmune, la colangitis esclerosante primaria y la cirrosis biliar primaria, en las que la respectiva evoluci&oacute;n no est&aacute; influenciada por la introducci&oacute;n de dieta sin gluten; y c) insuficiencia hep&aacute;tica grave y cirrosis hep&aacute;tica criptog&eacute;nica descompensada, potencialmente tratables con la dieta sin gluten.    <BR> Todas estas patolog&iacute;as est&aacute;n condicionadas por diferentes factores individuales y por una predisposici&oacute;n gen&eacute;tica. La progresi&oacute;n y la reversibilidad del da&ntilde;o hep&aacute;tico en los diferentes cuadros patol&oacute;gicos, pueden estar condicionadas por la exposici&oacute;n al gluten y la edad, precoz o tard&iacute;a, en la cual ha sido introducido en la dieta. Hay suficiente evidencia cl&iacute;nica para recomendar un atento cribado cruzado tanto para el diagn&oacute;stico del da&ntilde;o hep&aacute;tico asintom&aacute;tico en los pacientes con EC como para el diagn&oacute;stico de la EC en los pacientes con da&ntilde;o hep&aacute;tico criptog&eacute;nico.</P> <B>    <P>Palabras clave:</B> Enfermedad celiaca. Hepatopat&iacute;a. Anti-tTG. Transaminasas.</P> </FONT>    <P><HR SIZE=0> <B><FONT FACE="Verdana" SIZE=2>    <P>ABSTRACT</P> </B>    <P>Celiac disease (CD) is an important cause of serum aminotransferase elevation: between 5 and 10% of patients with persistent and cryptogenetic transaminase elevation may have CD. In fact, a wide spectrum of liver injuries in children and adults may be related to CD, particularly: a) mild parenchymal damage characterized by absence of any clinical signs or symptoms suggesting chronic liver disease, and by non-specific histological changes reversible on a gluten-free diet; b) chronic liver damage with autoimmune etiology, including autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis, which may be associated with CD but are generally unaffected by gluten withdrawal; and c) severe liver failure and decompensated cryptogenetic liver cirrhosis, potentially treatable with a gluten-free diet. Such different types of liver injuries may represent one same disorder where individual factors, such as genetic predisposition, precocity, and duration of exposure to gluten may influence reversibility of liver damage. A rigorous cross-checking for asymptomatic liver damage in CD individuals and, conversely, for CD in any cryptogenic liver disorder, including end-stage liver failure, is recommended.</P> <B>    ]]></body>
<body><![CDATA[<P>Key words:</B> Celiac disease. Liver disease. Anti-tTG. Transaminase.</P> </FONT>    <P><HR SIZE=0>     <P>&nbsp;</P> <B><FONT FACE="Verdana">    <P>Introducci&oacute;n</P> </B></FONT><FONT FACE="Verdana" SIZE=2>    <P>Las alteraciones hep&aacute;ticas en los pacientes con enfermedad cel&iacute;aca (EC) fueron descritas por primera vez por Pollock en 1977 (1), revisando las biopsias hep&aacute;ticas de 19 pacientes con malabsorci&oacute;n, en su mayor parte secundaria a EC. En tres casos el diagn&oacute;stico fue de hepatitis cr&oacute;nica, en uno de cirrosis y en otro de carcinoma hepatocelular, siendo los otros casos diagnosticados de cambios m&iacute;nimos asociados a veces con fibrosis o inflamaci&oacute;n periportal. Desde entonces la EC ha sido implicada en diferentes patolog&iacute;as hep&aacute;ticas (2-4) incluyendo hepatopat&iacute;as autoinmunes (5,6) e hipertransaminasemia criptog&eacute;nica (7-10). Adem&aacute;s, numerosos estudios han asociado la EC con cirrosis biliar primaria (11-14) y colangitis esclerosante primaria (15-17). Por &uacute;ltimo, la EC ha sido tambi&eacute;n asociada con patolog&iacute;a hep&aacute;tica descompensada y con estadios preterminales de enfermedades hep&aacute;ticas (4,18). Un reciente estudio epidemiol&oacute;gico (19) realizado en Suecia confirma que los pacientes celiacos tienen un mayor riesgo tanto de padecer enfermedades hep&aacute;ticas como de desarrollar patolog&iacute;a hepatica m&aacute;s avanzada, y a la inversa, los pacientes con patolog&iacute;a hep&aacute;tica tienen un mayor riesgo de padecer EC. El objetivo de esta revisi&oacute;n es valorar la frecuencia y la relevancia de la patolog&iacute;a hep&aacute;tica asociada a la EC y a la inversa, de la EC asociada a patolog&iacute;a hep&aacute;tica.</P> </FONT>    <P>&nbsp;</P> <B><FONT FACE="Verdana">    <P>Patolog&iacute;a hep&aacute;tica asociada al diagn&oacute;stico de enfermedad cel&iacute;aca</P> </B></FONT><FONT FACE="Verdana" SIZE=2>    <P>La elevaci&oacute;n de las transaminasas es un hallazgo bastante frecuente en los pacientes con EC no tratada (20). Despu&eacute;s del estudio de Hagander y cols. (7) en el que, en 1977, se describe por primera vez la elevaci&oacute;n de las transaminasas en el 55% de 74 pacientes adultos con EC no tratada, han sido publicados numerosos estudios (<A HREF="#t1">Tabla I</A>) que ponen de manifiesto prevalencias similares tanto en adultos como en pacientes de edad pedi&aacute;trica. Un resultado com&uacute;n en todos los estudios es la normalizaci&oacute;n de las transaminasas en el 95% de los pacientes en el primer a&ntilde;o de dieta sin gluten. S&oacute;lo el estudio de Bardella y cols. (8) describe con detalle el nivel medio de las transaminasas siendo de 61 (rango 25-470) para la ALT y de 47 (30-190) para la AST, lo que demuestra que la elevaci&oacute;n, normalmente leve, puede en alg&uacute;n caso ser mayor de 10 veces el valor normal. Estudios que incluyen una valoraci&oacute;n histol&oacute;gica del da&ntilde;o hep&aacute;tico, a veces publicados como casos cl&iacute;nicos, describen con elevada frecuencia patrones histol&oacute;gicos de h&iacute;gado normal, o de hepatitis inespec&iacute;fica y con menor frecuencia lesiones avanzadas con fibrosis y cirrosis hep&aacute;tica. En un an&aacute;lisis sistem&aacute;tico (23) realizado en 47 pacientes, la histolog&iacute;a hep&aacute;tica fue normal en 5 y present&oacute; cambios no espec&iacute;ficos en 35. En 6 casos se diagnostic&oacute; una hepatitis cr&oacute;nica activa y en 1 caso una colangitis esclerosante primaria asociada tambi&eacute;n a colitis ulcerosa. En la <A HREF="#t2">tabla II</A> se resumen en detalle los cambios descritos en las biopsias. Parece oportuno subrayar como patrones m&aacute;s frecuentes el ensanchamiento del espacio porta (48%), la destrucci&oacute;n de conductos biliares (36%), el aumento de las c&eacute;lulas de Kupffer (52%) y, por &uacute;ltimo, la esteatosis hep&aacute;tica en m&aacute;s del 25% de los hepatocitos (38%). En los pacientes con EC y elevaci&oacute;n de transaminasas no se han observado diferencias cl&iacute;nicas, antropom&eacute;tricas, epidemiol&oacute;gicas o histol&oacute;gicas, con respecto a los casos con EC sin alteraci&oacute;n hep&aacute;tica (8). La normalizaci&oacute;n de los valores de transaminasas suele ocurrir, en la mayor&iacute;a de los casos (80%), en los primeros seis meses despu&eacute;s de la introducci&oacute;n de la dieta sin gluten (23) y en casi todos (95%) en los primeros 12 meses, lo que indica la necesidad de descartar otras causas de da&ntilde;o hep&aacute;tico en aquellos pacientes con elevaci&oacute;n persistente de las transaminasas y que cumplen correctamente con la dieta. En la <A HREF="#t3">tabla III</A> se resumen los diagn&oacute;sticos observados en los 7 pacientes de una cohorte de 158 que no normalizaron las transaminasas despu&eacute;s de un a&ntilde;o de dieta sin gluten (8).</P></FONT>     <P ALIGN="CENTER"><A NAME="t1"><IMG SRC="/img/revistas/diges/v99n11/punto_de_vista_03.jpg" WIDTH=379 HEIGHT=225></A></P>     <P ALIGN="CENTER">&nbsp;</P>     ]]></body>
<body><![CDATA[<P ALIGN="CENTER"><A NAME="t2"><IMG SRC="/img/revistas/diges/v99n11/punto_de_vista_06.jpg" WIDTH=379 HEIGHT=216></A></P>     <P ALIGN="CENTER">&nbsp;</P>     <P ALIGN="CENTER"><A NAME="t3"><IMG SRC="/img/revistas/diges/v99n11/punto_de_vista_08.jpg" WIDTH=379 HEIGHT=218></A></P>     <P ALIGN="CENTER">&nbsp;</P> <FONT FACE="Verdana" SIZE=2>    <P>Los mecanismos patog&eacute;nicos del da&ntilde;o hep&aacute;tico en los pacientes con EC son poco conocidos. Una de las hip&oacute;tesis m&aacute;s aceptadas est&aacute; basada en que el incremento de la permeabilidad intestinal observada en los pacientes celiacos podr&iacute;a favorecer la absorci&oacute;n de ant&iacute;genos procedentes del intestino a trav&eacute;s de la circulaci&oacute;n portal. En un estudio (9) que avala esta hip&oacute;tesis se realiz&oacute; un test de permeabilidad intestinal con lactulosa y manitol a 72 pacientes con EC y elevaci&oacute;n de las transaminasas en el momento del diagn&oacute;stico. Despu&eacute;s de un a&ntilde;o de dieta sin gluten, los valores de transaminasas se normalizaron en 64 pacientes y persistieron elevados en los 8 restantes. En estos &uacute;ltimos la permeabilidad intestinal result&oacute; m&aacute;s elevada que en los 64 pacientes con transaminasas normales (0,34 vs. 0,11; p = 0,0001). En 5 de los 8 pacientes con persistencia de hipertransaminasemia despu&eacute;s de un a&ntilde;o de dieta sin gluten, se realiz&oacute; una biopsia hep&aacute;tica que permiti&oacute; diagnosticar hepatitis cr&oacute;nica con fibrosis en 2 casos y m&iacute;nimo infiltrado linfoc&iacute;tico portal en los 3 restantes. Un incremento de la permeabilidad intestinal a los ant&iacute;genos intraluminales puede producir, en sujetos gen&eacute;ticamente predispuestos, una respuesta inmune dirigida contra antigenos que comparten ep&iacute;topos propios de las prote&iacute;nas hep&aacute;ticas y/o contra ant&iacute;genos de la mucosa intestinal, desenmascarados por la reacci&oacute;n con la gliadina. Est&aacute; claramente demostrado que el da&ntilde;o de la mucosa intestinal en la EC est&aacute; inducido por la acci&oacute;n de la enzima transglutaminasa tisular (tTG), que juega el papel de ant&iacute;geno diana o auto-ant&iacute;geno para los anticuerpos antiendomisio (28). En efecto, la inmunidad humoral est&aacute; involucrada en la patog&eacute;nesis de la EC y la tTG, como auto-ant&iacute;geno, puede tener un papel relevante tambi&eacute;n en las manifestaciones extraintestinales de la EC, y en particular en el da&ntilde;o hep&aacute;tico. Esta hip&oacute;tesis ha sido confirmada en un reciente estudio (29) que ha observado el dep&oacute;sito de anticuerpos de clase IgA anti-tTG en las biopsias hep&aacute;ticas de dos pacientes con EC activa. La tTG es una enzima ubicua que juega un papel fundamental en la homeostasis del ciclo celular: proliferaci&oacute;n, diferenciaci&oacute;n y apoptosis (30), y est&aacute; involucrada en las interacciones entre las c&eacute;lulas y la matriz extracelular y tambi&eacute;n en los procesos de remodelaci&oacute;n y estabilizaci&oacute;n de la matriz extracelular (31). Ha sido descrito que los auto-anticuerpos anti-tTG en la EC inhiben la actividad de la enzima en la producci&oacute;n de <I>cross-linking</I> entre prote&iacute;nas e interfieren en los cambios fisiol&oacute;gicos de la matriz extracelular y en la producci&oacute;n de citoquinas. Tambi&eacute;n se ha observado una alteraci&oacute;n de la adhesi&oacute;n celular mediada por tTG (32), as&iacute; como una alteraci&oacute;n de la funci&oacute;n nutritiva y de la arquitectura de la mucosa en relaci&oacute;n con el dep&oacute;sito de anticuerpos IgA anti-tTG (29). Por &uacute;ltimo, los anticuerpos anti-tTG pueden ser directamente patog&eacute;nicos, mediante la generaci&oacute;n de nuevos ep&iacute;topos antig&eacute;nicos y la activaci&oacute;n de la respuesta de las c&eacute;lulas T (33). Estas hip&oacute;tesis permiten considerar la EC como una enfermedad sist&eacute;mica ayudando a explicar las m&uacute;ltiples manifestaciones extraintestinales asociadas.</P> </FONT>    <P>&nbsp;</P> <B><FONT FACE="Verdana">    <P>Enfermedad celiaca asociada al diagn&oacute;stico de hepatopat&iacute;as cr&oacute;nicas</P> </FONT><FONT FACE="Verdana" SIZE=2>    <P>Hepatitis criptogen&eacute;tica y esteatohepatitis no alcoh&oacute;lica</P> </B>    <P>En el 10% de los pacientes con elevaci&oacute;n asintom&aacute;tica pero persistente de los valores de transaminasas, la etiolog&iacute;a del da&ntilde;o hep&aacute;tico es indeterminada o est&aacute; asociada a estatohepatitis no alcoh&oacute;lica (EHNA). En estos grupos, la EC ha sido descrita como &uacute;nica causa de da&ntilde;o hep&aacute;tico entre el 4 y el 10% de los pacientes con hepatitis criptogen&eacute;tica (3,34-37) y en el 4% de los casos con EHNA (2,38). La elevada prevalencia de la EC, estimada entre 1 y 3% en la poblaci&oacute;n general de los pa&iacute;ses occidentales, y la elevada frecuencia de la presentaci&oacute;n <I>at&iacute;pica</I> o subcl&iacute;nica de la enfermedad, que puede manifestarse con la elevaci&oacute;n de los valores de transaminasas como &uacute;nico indicio, motiva la necesidad de realizar un cribado para descartar la EC en todos los pacientes con elevaci&oacute;n de los valores de transaminasas sin otra causa de patolog&iacute;a hep&aacute;tica. La elevada frecuencia de ambas patolog&iacute;as dificulta la identificaci&oacute;n de claros mecanismos patog&eacute;nicos. Parece relevante subrayar la ausencia de relaci&oacute;n con el &iacute;ndice de masa corporal (IMC), normal o elevado en la mayor&iacute;a de los casos; y la presencia de lesiones histol&oacute;gicas hep&aacute;ticas no espec&iacute;ficas con frecuencia asociadas a esteatosis. En algunos pacientes con persistencia de la elevaci&oacute;n de los valores de transaminasas despu&eacute;s de un a&ntilde;o de dieta sin gluten, la esteatosis puede persistir como &uacute;nico da&ntilde;o histol&oacute;gico. Por &uacute;ltimo, es importante recordar la posibilidad, aunque relativamente rara, de encontrar resultados falsos positivos de anti-tTG IgA o IgG en los pacientes con enfermedad hep&aacute;tica cr&oacute;nica por diferentes etiolog&iacute;as. Nuestro grupo ha demostrado recientemente el papel de la tTg en los procesos de fibrosis hep&aacute;tica (39) y estos resultados falsos positivos pueden estar justificados por la expresi&oacute;n de transglutaminasa tisular en relaci&oacute;n con el estadio de la fibrosis hep&aacute;tica (40). Para reducir el riesgo de resultados falsos positivos en los pacientes con hepatitis cr&oacute;nica hemos propuesto (10) el uso de IgG anti-tTG en asociaci&oacute;n con IgA anti-tTG obteniendo la misma sensibilidad y especificidad de los anticuerpos anti endomisio (EmA). La combinaci&oacute;n de los dos tests, IgA e IgG anti-tTG, realizados mediante t&eacute;cnica de ELISA, resulta m&aacute;s econ&oacute;mica y m&aacute;s f&aacute;cil de realizar que la t&eacute;cnica de inmunofluorescencia necesaria para detectar los anticuerpos anti-endomisio (EmA) como test de confirmaci&oacute;n y se ha demostrado diagn&oacute;stica incluso en el 10% de pacientes celiacos con d&eacute;ficit de IgA.</P> <B>    <P>Cirrosis biliar primaria (CBP)</P> </B>    ]]></body>
<body><![CDATA[<P>En la <A HREF="#t4">tabla IV</A> se resumen los estudios que han valorado la EC en pacientes con CBP estimando su frecuencia entre 0 y 7%. La amplia disparidad de resultados puede estar justificada por la distinta metodolog&iacute;a y por el n&uacute;mero limitado de pacientes valorados en la mayor&iacute;a de los estudios. A la inversa, la frecuencia de diagn&oacute;stico de CBP en pacientes con EC se estima entre 0 y 3%. Un reciente estudio epidemiol&oacute;gico ha confirmado en una amplia cohorte esta evidencia, y ha estimado que los pacientes con EC tienen un riesgo de padecer CBP 4 veces mayor respecto a la poblaci&oacute;n general (19). Sin embargo, la instauraci&oacute;n de una dieta sin gluten no modifica la evoluci&oacute;n de la CBP. Teniendo en cuenta que la p&eacute;rdida de peso, la malabsorci&oacute;n (por diferentes mecanismos), y la osteoporosis son manifestaciones cl&iacute;nicas comunes a ambas entidades, el cribado de CBP mediante la determinaci&oacute;n de anticuerpos anti-mitocondriales en pacientes con EC, y a la inversa, parece una estrategia razonable para realizar un diagn&oacute;stico precoz y llevar a cabo medidas terap&eacute;uticas espec&iacute;ficas (40).</P> </FONT>    <P ALIGN="CENTER"><A NAME="t4"><IMG SRC="/img/revistas/diges/v99n11/punto_de_vista_10.jpg" WIDTH=379 HEIGHT=239></A></P>     <P>&nbsp;</P> <B><FONT FACE="Verdana" SIZE=2>    <P>Hepatitis cr&oacute;nica autoinmune (HA)</P> </B>    <P>La posible asociaci&oacute;n entre EC y HA ha sido descrita en varias publicaciones, casi siempre valorando un limitado n&uacute;mero de pacientes. En estos &uacute;ltimos a&ntilde;os, estudiando un mayor n&uacute;mero de casos, la prevalencia de la EC en pacientes con HA ha sido estimada en el 4%, tanto en adultos (5) como en ni&ntilde;os (49). A la inversa, los pacientes con EC tienen un riesgo de padecer una HA 6 veces mayor que la poblaci&oacute;n general (19). En la mayor&iacute;a de estos pacientes la EC es asintom&aacute;tica y normalmente el diagn&oacute;stico de HA precede al diagn&oacute;stico de EC. Para explicar esta asociaci&oacute;n es importante observar que la EC y la HA comparten determinadas combinaciones de genes que codifican los ant&iacute;genos HLA de clase II. En la poblaci&oacute;n occidental han sido identificados dos aplotipos asociados con una mayor susceptibilidad a las HA: el complejo HLA A1 B8 DR3 y el haplotipo HLA DR4. Igualmente HLA-DR3 y en particular la expresi&oacute;n de mol&eacute;culas DQ2 y DQ8 se asocia con una mayor susceptibilidad a desarrollar EC. En un estudio de Volta y cols., de 8 casos diagnosticados de EC entre un grupo de 181 pacientes con HA, 7 presentaban un aplotipo DQ2, en 5 casos asociado con DR3, en un caso con DR7, en otro con DR8 y s&oacute;lo en un caso present&oacute; un aplotipo diferente (A24B8) (5).</P>     <P>En conclusi&oacute;n, est&aacute; indicado realizar el cribado de EC en pacientes con HA y, a la inversa, el cribado de HA en pacientes con EC y elevaci&oacute;n de los valores de las enzimas hep&aacute;ticas para establecer las medidas terape&uacute;ticas oportunas en las dos patolog&iacute;as. En cualquier caso, en esta asociaci&oacute;n la dieta sin gluten tampoco parece favorecer una mejor&iacute;a del da&ntilde;o hep&aacute;tico, y la terapia inmunosupresora deber&aacute; instaurarse con las pautas habituales.</P> <B>    <P>Enfermedad hep&aacute;tica terminal</P> </B>    <P>Un aspecto de la EC actualmente muy debatido es la valoraci&oacute;n de la EC como posible causa, potencialmente tratable, de fallo hep&aacute;tico (50). En un estudio reciente (4), realizado en Finlandia, cribando un grupo de 185 pacientes adultos incluidos en lista de espera para trasplante hep&aacute;tico, se ha observado que 8 pacientes (4,3%) eran cel&iacute;acos. En la mayor&iacute;a de los casos la etiolog&iacute;a de la hepatitis era autoinmune. El aspecto m&aacute;s relevante de este estudio es la dram&aacute;tica mejor&iacute;a de la funci&oacute;n hep&aacute;tica despu&eacute;s de la introducci&oacute;n de la dieta sin gluten observada en 4 pacientes, hasta el punto que tres de ellos pudieron salir de la lista de trasplante. Un caso similar ha sido descrito por Ojetti y cols. (51): una mujer de 28 a&ntilde;os de edad que presentaba un fallo hep&aacute;tico agudo de etiolog&iacute;a desconocida, fue diagnosticada de EC durante el protocolo de valoraci&oacute;n pretrasplante. La introducci&oacute;n de la dieta sin gluten ha sido asociada con una r&aacute;pida mejor&iacute;a de la funci&oacute;n hep&aacute;tica. Casos de EC asociados a cirrosis, a enfermedad hep&aacute;tica preterminal y con necesidad de trasplante hep&aacute;tico han sido descrito tambi&eacute;n en ni&ntilde;os (52).</P> </FONT>    <P>&nbsp;</P> <B><FONT FACE="Verdana">    <P>Conclusiones</P> </B></FONT><FONT FACE="Verdana" SIZE=2>    ]]></body>
<body><![CDATA[<P>Las numerosas evidencias reflejadas en esta revisi&oacute;n son suficientes, en nuestra opini&oacute;n, y a falta de adecuados an&aacute;lisis prospectivos y de coste-efectividad, para recomendar un riguroso cribado cruzado de da&ntilde;o hep&aacute;tico asintom&aacute;tico en los sujetos con EC e hipertransaminasemia persistente despu&eacute;s del inicio de dieta sin gluten y, viceversa, de EC, mediante la apropiada serolog&iacute;a, en todas las enfermedades hep&aacute;ticas criptogen&eacute;ticas o autoinmunes incluyendo los pacientes con enfermedad descompensada o en lista de espera para trasplante hep&aacute;tico.</P>     <P>Por &uacute;ltimo, hay que recordar que en los pacientes con enfermedad hep&aacute;tica cr&oacute;nica hay una probabilidad m&aacute;s elevada de falsos positivos para anti-transglutaminasa debido, en algunos casos, a la elevada concentraci&oacute;n de inmunoglobulinas y, en la mayor&iacute;a, al papel de la transglutaminasa en los mecanismos de fibrosis hep&aacute;tica. Por lo tanto, es aconsejable en estos pacientes realizar el cribado serol&oacute;gico de EC asociando al test anti-tTG IgA tambi&eacute;n la determinaci&oacute;n de anti-tTG IgG o anti-EmA.</P> </FONT>    <P>&nbsp;</P> <B><FONT FACE="Verdana">    <P>Bibliograf&iacute;a</P> </B></FONT><FONT FACE="Verdana" SIZE=2>    <!-- ref --><P>1.Pollock DJ. The liver in coeliac disease. Histopathology 1977; 1: 421-30.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296408&pid=S1130-0108200700110000500001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>2.Bardella MT, Valenti L, Pagliari C, et al. Searching for celiac disease in patients with non-alcoholic fatty liver disease. Dig Liver Dis 2004; 36: 333-6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296409&pid=S1130-0108200700110000500002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>3.Bardella MT, Vecchi M, Conte D, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999; 29: 654-7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296410&pid=S1130-0108200700110000500003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>4.Kaukinen K, Halme L, Collin P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002; 122: 881-8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296411&pid=S1130-0108200700110000500004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>5.Volta U, De Franceschi L, Molinaro N, et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998; 43: 2190-5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296412&pid=S1130-0108200700110000500005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>6.Villalta D, Girolami D, Bidoli E, et al. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies. J Clin Lab Anal 2005; 19: 6-10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296413&pid=S1130-0108200700110000500006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>7.Hagander B, Berg NO, Brandt L, Norden A, Sjolund K, Stenstam M. Hepatic injury in adult coeliac disease. Lancet 1977; 2: 270-2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296414&pid=S1130-0108200700110000500007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>8.Bardella MT, Fraquelli M, Quatrini M, et al. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology 1995; 22: 833-6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296415&pid=S1130-0108200700110000500008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>9.Novacek G, Miehsler W, Wrba F, et al. Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. Eur J Gastroenterol Hepatol 1999; 11: 283-8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296416&pid=S1130-0108200700110000500009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>10.Lo Iacono O, Petta S, Venezia G, Di Marco V, Tarantino G, Barbaria F, et al. Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: Is it always coeliac disease? Am J Gastroenterol 2005; 100: 2472-7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296417&pid=S1130-0108200700110000500010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>11.Logan RF, Ferguson A, Finlayson ND, et al. Primary biliary cirrhosis and coeliac disease: An association? Lancet 1978; 1: 230-3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296418&pid=S1130-0108200700110000500011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>12.Sorensen HT, Thulstrup AM, Blomqvist P, et al. Risk of primary biliary liver cirrhosis in patients with coeliac disease: Danish and Swedish cohort data. Gut 1999; 44: 736-8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296419&pid=S1130-0108200700110000500012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>13.Lawson A, West J, Aithal GP, et al. Autoimmune cholestatic liver disease in people with coeliac disease: A population-based study of their association. Aliment Pharmacol Ther 2005; 21: 401-5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296420&pid=S1130-0108200700110000500013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>14.Hay JE, Wiesner RH, Shorter RG, et al. Primary sclerosing cholangitis and celiac disease: a novel association. Ann Intern Med 1988; 109: 713-7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296421&pid=S1130-0108200700110000500014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>15.Gillberg R, Dotevall G, Ahren C. Chronic inflammatory bowel disease in patients with coeliac disease. Scand J Gastroenterol 1982; 17: 491-6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296422&pid=S1130-0108200700110000500015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>16.Volta U, Rodrigo L, Granito A, et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol 2002; 97: 2609-13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296423&pid=S1130-0108200700110000500016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>17.Al-Osaimi AM, Berg CL. Association of primary sclerosing cholangitis and celiac disease: A case report and review of the literature. Dig Dis Sci 2004; 49: 438-43.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296424&pid=S1130-0108200700110000500017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>18.Peters U, Askling J, Gridley G, et al. Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med 2003; 163: 1566-72.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296425&pid=S1130-0108200700110000500018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>19.Ludvigsson JF, Elfstrom P, Broome U, Ekbom A, Montgomery SM. Celiac disease and risk of liver disease: A general population-based study. Clin Gastroenterol Hepatol 2007; 5: 63-9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296426&pid=S1130-0108200700110000500019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>20.Duggan JM, Duggan A E. Systematic review: The liver in coeliac disease Aliment Pharmacol Ther 2005; 21: 515-8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296427&pid=S1130-0108200700110000500020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>21.Lindberg T, Berg NO, Borulf S, Jakobsson I. Liver damage in coeliac disease or other food intolerance in childhood. Lancet 1978; 18; 1: 390-1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296428&pid=S1130-0108200700110000500021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>22.Bonamico M, Pitzalis G, Culasso F, Vania A, Monti S, Benedetti C, et al. Hepatic damage in celiac disease in children Minerva Pediatr 1986; 15; 38: 959-62.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296429&pid=S1130-0108200700110000500022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>23.Jacobsen MB, Fausa O, Elgjo K, Schrumpf E. Hepatic lesions in adult coeliac disease. Scand J Gastroenterol 1990; 25: 656-62.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296430&pid=S1130-0108200700110000500023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>24.Morillas MJ, Gaspar E, Moles JR, Siles S, Garcia E, Nos P, et al. Adult celiac disease and hepatopathy. Rev Esp Enferm Dig 1991; 79: 197-200.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296431&pid=S1130-0108200700110000500024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>25.Dickey W, McMillan SA, Collins JS, Watson RG, McLoughlin JC, Love AH. Liver abnormalities associated with celiac sprue. How common are they, what is their significance, and what do we do about them? J Clin Gastroenterol 1995; 20: 290-2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296432&pid=S1130-0108200700110000500025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>26.Farre C, Esteve M, Curcoy A, Cabre E, Arranz E, Amat LL, et al. Hypertransaminasemia in pediatric celiac disease patients and its prevalence as a diagnostic clue. Am J Gastroenterol. 2002; 97: 3176-81.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296433&pid=S1130-0108200700110000500026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>27.Arslan N, Buyukgebiz B, Ozturk Y, Ozer E. The prevalence of liver function abnormalities in pediatric celiac disease patients and its relation with intestinal biopsy findings. Acta Gastroenterol Belg 2005; 68: 424-7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296434&pid=S1130-0108200700110000500027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>28.Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken E, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3: 797-801.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296435&pid=S1130-0108200700110000500028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>29.Korponay Szabo IR, Halttunen T, Szalai Z, Laurila K, Kiraly R, Kovacs JB, et al. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 2004; 53: 641-8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296436&pid=S1130-0108200700110000500029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>30.Schuppan D. Current concepts of celiac disease pathogenesis. Gastroenterology. 2000; 119: 234-42.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296437&pid=S1130-0108200700110000500030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>31.Griffin M, Casadio R, Bergamini CM. Transglutaminases: Nature’s biological glues. Biochem J 2002; 368: 377-96.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296438&pid=S1130-0108200700110000500031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>32.Kainulainen H, Rantala I, Collin P, et al. Blisters in the small intestinal mucosa of coeliac patients contain T cells positive for cyclooxygenase 2. Gut 2002; 50: 84-9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296439&pid=S1130-0108200700110000500032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>33.Korponay Szabo IR, Sulkanen S, Halttunen T, Maurano F, Rossi M, Mazzarella G, et al. Tissue transglutaminase is the target in both rodent and primate tissues for celiac disease-specific autoantibodies. J Pediatr Gastroenterol Nutr 2000; 31 (5): 520-7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296440&pid=S1130-0108200700110000500033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>34.Lindgren S, Sjoberg K, Eriksson S. Unsuspected coeliac disease in chronic "cryptogenic" liver disease. Scand J Gastroenterol 1994; 29: 661-4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296441&pid=S1130-0108200700110000500034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>35.Volta U, De Franceschi L, Lari F, et al. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998; 352: 26-9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296442&pid=S1130-0108200700110000500035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>36.Gonz&aacute;lez Abraldes J, S&aacute;nchez-Fueyo A, Bessa X, et al. Persistent hypertransaminasemia as the presenting feature of coeliac disease. Am J Gastroenterol 1999; 94: 1095-7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296443&pid=S1130-0108200700110000500036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>37.Volta U, Granito A, De Franceschi L, et al. Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin. Dig Liver Dis 2001; 33: 420-5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296444&pid=S1130-0108200700110000500037&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>38.Franzese A, Iannucci MP, Valerio G, et al. Atypical coeliac disease presenting as obesity-related liver dysfunction. J Pediatr Gastroenterol Nutr 2001; 33: 329-32.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296445&pid=S1130-0108200700110000500038&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>39.Nardacci R, Lo Iacono O, Ciccosanti F, Falasca L, Addesso M, Amendola A, et al. Transglutaminase type II plays a protective role in hepatic injury. Am J Pathol 2003; 162: 1293-303.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296446&pid=S1130-0108200700110000500039&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>40.Floreani A, Betterle C, Baragiotta A, Martini S, Venturi C, Basso D, et al. Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy. Dig Liver Dis 2002; 34 (4): 258-61.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296447&pid=S1130-0108200700110000500040&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>41.Olsson R, Kagevi I, Rydberg L. On the concurrence of primary biliary cirrhosis and intestinal villous atrophy. Scand J Gastroenterol 1982; 17: 625-8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296448&pid=S1130-0108200700110000500041&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>42.Lofgren J, Jarnerot G, Danielsson D, Hemdal I. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand J Gastroenterol 1985; 20: 647-50.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296449&pid=S1130-0108200700110000500042&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>43.Sjoberg K, Lindgren S, Eriksson S. Frequent occurrence of non-specific gliadin antibodies in chronic liver disease. Endomysial but not gliadin antibodies predict coeliac disease in patients with chronic liver disease. Scand J Gastroenterol 1997; 32: 1162-7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296450&pid=S1130-0108200700110000500043&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>44.Dickey W, McMillan SA, Callender ME. High prevalence of celiac sprue among patients with primary biliary cirrhosis. J Clin Gastroenterol 1997; 25: 328-9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296451&pid=S1130-0108200700110000500044&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>45.Bardella MT, Quatrini M, Zuin M, Podda M, Cesarini L, Velio P, et al. Screening patients with celiac disease for primary biliary cirrhosis and viceversa. Am J Gastroenterol 1997; 92: 1524-6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296452&pid=S1130-0108200700110000500045&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>46.Kingham JG, Parker DR. The association between primary biliary cirrhosis and coeliac disease: A study of relative prevalences. Gut 1998; 42: 120-2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296453&pid=S1130-0108200700110000500046&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>47.Niveloni S, Dezi R, Pedreira S, Podesta A, Cabanne A, V&aacute;zquez H, et al. Gluten sensitivity in patients with primary biliary cirrhosis. Am J Gastroenterol 1998; 93: 404-8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296454&pid=S1130-0108200700110000500047&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>48.Gillett HR, Freeman HJ. Prevalence of celiac disease in collagenous and lymphocytic colitis. Can J Gastroenterol. 2000; 14: 919-21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296455&pid=S1130-0108200700110000500048&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>49.Francavilla R, Castellaneta SP, Davis T, Hadzic N, Mieli Vergani G. Coeliac disease in children with autoimmune hepatitis. Dig Liver Dis 2001; 33: 624 (abstract).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296456&pid=S1130-0108200700110000500049&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>50.Stevens FM, McLoughlin RM. Is coeliac disease a potentially treatable cause of liver failure? Eur J Gastroenterol Hepatol 2005; 17: 1015-7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296457&pid=S1130-0108200700110000500050&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>51.Ojetti V, Fini l, Zileri Dal Verme L, Migneco A, Pola P, Gasbarrini A. Acute cryptogenic liver failure in an untreated coeliac patient: A case report. Eur J Gastroenterol Hepatol 2005; 17: 1119-21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296458&pid=S1130-0108200700110000500051&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P>52.Pavone P, Guttadauria S, Leonardi S, et al. Liver transplantation in a child with celiac disease. J Gastroenterol Hepatol 2005; 20: 956-60.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=5296459&pid=S1130-0108200700110000500052&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><P>&nbsp;</P>     <P>&nbsp;</P>     <P><B><FONT FACE="Verdana" SIZE=2><a href="#top"><img border="0" src="/img/revistas/diges/v99n11/seta.gif" width="15" height="17"></a><a name="back"></a>Direcci&oacute;n para correspondencia: </FONT></B><FONT FACE="Verdana" SIZE=2>    <BR> Oreste Lo Iacono.    ]]></body>
<body><![CDATA[<BR> Secci&oacute;n de Hepatolog&iacute;a. Servicio de Aparato Digestivo.    <BR> Hospital General Universitario Gregorio Mara&ntilde;&oacute;n.    <BR> C/ Dr. Esquerdo, 46. 28007 Madrid.    <BR> Fax: 914 265 164.    <BR> e-mail: </FONT><A HREF="mailto:oreloia@hotamil.com"><FONT FACE="Verdana" SIZE=2>oreloia@hotamil.com</FONT></A></P>     <P><FONT FACE="Verdana" SIZE=2>Recibido: 20-04-07.    <BR> Aceptado: 11-05-07.</P> </FONT>     ]]></body>
<back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pollock]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The liver in coeliac disease]]></article-title>
<source><![CDATA[Histopathology]]></source>
<year>1977</year>
<volume>1</volume>
<page-range>421-30</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bardella]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Valenti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pagliari]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Searching for celiac disease in patients with non-alcoholic fatty liver disease]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2004</year>
<volume>36</volume>
<page-range>333-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bardella]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Vecchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Conte]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Chronic unexplained hypertransaminasemia may be caused by occult celiac disease]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>1999</year>
<volume>29</volume>
<page-range>654-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaukinen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Halme]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Collin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2002</year>
<volume>122</volume>
<page-range>881-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volta]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[De Franceschi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Molinaro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis]]></article-title>
<source><![CDATA[Dig Dis Sci]]></source>
<year>1998</year>
<volume>43</volume>
<page-range>2190-5</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villalta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Girolami]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bidoli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies]]></article-title>
<source><![CDATA[J Clin Lab Anal]]></source>
<year>2005</year>
<volume>19</volume>
<page-range>6-10</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hagander]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[NO]]></given-names>
</name>
<name>
<surname><![CDATA[Brandt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Norden]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sjolund]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Stenstam]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatic injury in adult coeliac disease]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1977</year>
<volume>2</volume>
<page-range>270-2</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bardella]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Fraquelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Quatrini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>1995</year>
<volume>22</volume>
<page-range>833-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novacek]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Miehsler]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wrba]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence and clinical importance of hypertransaminasaemia in coeliac disease]]></article-title>
<source><![CDATA[Eur J Gastroenterol Hepatol]]></source>
<year>1999</year>
<volume>11</volume>
<page-range>283-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lo Iacono]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Petta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Venezia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Di Marco]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Tarantino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Barbaria]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: Is it always coeliac disease?]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2005</year>
<volume>100</volume>
<page-range>2472-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Logan]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Finlayson]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Primary biliary cirrhosis and coeliac disease: An association?]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1978</year>
<volume>1</volume>
<page-range>230-3</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorensen]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Thulstrup]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Blomqvist]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk of primary biliary liver cirrhosis in patients with coeliac disease: Danish and Swedish cohort data]]></article-title>
<source><![CDATA[Gut]]></source>
<year>1999</year>
<volume>44</volume>
<page-range>736-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[West]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aithal]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autoimmune cholestatic liver disease in people with coeliac disease: A population-based study of their association]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2005</year>
<volume>21</volume>
<page-range>401-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hay]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Wiesner]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Shorter]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Primary sclerosing cholangitis and celiac disease: a novel association]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1988</year>
<volume>109</volume>
<page-range>713-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gillberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dotevall]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ahren]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Chronic inflammatory bowel disease in patients with coeliac disease]]></article-title>
<source><![CDATA[Scand J Gastroenterol]]></source>
<year>1982</year>
<volume>17</volume>
<page-range>491-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volta]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Granito]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Celiac disease in autoimmune cholestatic liver disorders]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2002</year>
<volume>97</volume>
<page-range>2609-13</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Osaimi]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Association of primary sclerosing cholangitis and celiac disease: A case report and review of the literature]]></article-title>
<source><![CDATA[Dig Dis Sci]]></source>
<year>2004</year>
<volume>49</volume>
<page-range>438-43</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Askling]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gridley]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Causes of death in patients with celiac disease in a population-based Swedish cohort]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2003</year>
<volume>163</volume>
<page-range>1566-72</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ludvigsson]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Elfstrom]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Broome]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Ekbom]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Montgomery]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Celiac disease and risk of liver disease: A general population-based study]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2007</year>
<volume>5</volume>
<page-range>63-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duggan]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Duggan]]></surname>
<given-names><![CDATA[A E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Systematic review: The liver in coeliac disease]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2005</year>
<volume>21</volume>
<page-range>515-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindberg]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[NO]]></given-names>
</name>
<name>
<surname><![CDATA[Borulf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jakobsson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Liver damage in coeliac disease or other food intolerance in childhood]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1978</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>390-1</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonamico]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pitzalis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Culasso]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vania]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Monti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Benedetti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatic damage in celiac disease in children]]></article-title>
<source><![CDATA[Minerva Pediatr]]></source>
<year>1986</year>
<volume>15</volume>
<numero>38</numero>
<issue>38</issue>
<page-range>959-62</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobsen]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Fausa]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Elgjo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Schrumpf]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatic lesions in adult coeliac disease]]></article-title>
<source><![CDATA[Scand J Gastroenterol]]></source>
<year>1990</year>
<volume>25</volume>
<page-range>656-62</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morillas]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gaspar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Moles]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Siles]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Adult celiac disease and hepatopathy]]></article-title>
<source><![CDATA[Rev Esp Enferm Dig]]></source>
<year>1991</year>
<volume>79</volume>
<page-range>197-200</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dickey]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[McMillan]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Watson]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[McLoughlin]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Love]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Liver abnormalities associated with celiac sprue: How common are they, what is their significance, and what do we do about them?]]></article-title>
<source><![CDATA[J Clin Gastroenterol]]></source>
<year>1995</year>
<volume>20</volume>
<page-range>290-2</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farre]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Esteve]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Curcoy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cabre]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Arranz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Amat]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hypertransaminasemia in pediatric celiac disease patients and its prevalence as a diagnostic clue]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2002</year>
<volume>97</volume>
<page-range>3176-81</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arslan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Buyukgebiz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ozturk]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ozer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The prevalence of liver function abnormalities in pediatric celiac disease patients and its relation with intestinal biopsy findings]]></article-title>
<source><![CDATA[Acta Gastroenterol Belg]]></source>
<year>2005</year>
<volume>68</volume>
<page-range>424-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dieterich]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ehnis]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Donner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Volta]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Riecken]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Identification of tissue transglutaminase as the autoantigen of celiac disease]]></article-title>
<source><![CDATA[Nat Med]]></source>
<year>1997</year>
<volume>3</volume>
<page-range>797-801</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Korponay Szabo]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Halttunen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Szalai]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Laurila]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kiraly]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kovacs]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2004</year>
<volume>53</volume>
<page-range>641-8</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schuppan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Current concepts of celiac disease pathogenesis]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2000</year>
<volume>119</volume>
<page-range>234-42</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Casadio]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bergamini]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transglutaminases: Nature’s biological glues]]></article-title>
<source><![CDATA[Biochem J]]></source>
<year>2002</year>
<volume>368</volume>
<page-range>377-96</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kainulainen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rantala]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Collin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Blisters in the small intestinal mucosa of coeliac patients contain T cells positive for cyclooxygenase 2]]></article-title>
<source><![CDATA[Gut]]></source>
<year>2002</year>
<volume>50</volume>
<page-range>84-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Korponay Szabo]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Sulkanen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Halttunen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Maurano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzarella]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tissue transglutaminase is the target in both rodent and primate tissues for celiac disease-specific autoantibodies]]></article-title>
<source><![CDATA[J Pediatr Gastroenterol Nutr]]></source>
<year>2000</year>
<volume>31</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>520-7</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindgren]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sjoberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Unsuspected coeliac disease in chronic "cryptogenic" liver disease]]></article-title>
<source><![CDATA[Scand J Gastroenterol]]></source>
<year>1994</year>
<volume>29</volume>
<page-range>661-4</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volta]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[De Franceschi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lari]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Coeliac disease hidden by cryptogenic hypertransaminasaemia]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1998</year>
<volume>352</volume>
<page-range>26-9</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Abraldes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Fueyo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bessa]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Persistent hypertransaminasemia as the presenting feature of coeliac disease]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>1999</year>
<volume>94</volume>
<page-range>1095-7</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volta]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Granito]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[De Franceschi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2001</year>
<volume>33</volume>
<page-range>420-5</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franzese]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Iannucci]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Valerio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Atypical coeliac disease presenting as obesity-related liver dysfunction]]></article-title>
<source><![CDATA[J Pediatr Gastroenterol Nutr]]></source>
<year>2001</year>
<volume>33</volume>
<page-range>329-32</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nardacci]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lo Iacono]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ciccosanti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Falasca]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Addesso]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Amendola]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transglutaminase type II plays a protective role in hepatic injury]]></article-title>
<source><![CDATA[Am J Pathol]]></source>
<year>2003</year>
<volume>162</volume>
<page-range>1293-303</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Floreani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Betterle]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Baragiotta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Venturi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Basso]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2002</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>258-61</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olsson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kagevi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rydberg]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[On the concurrence of primary biliary cirrhosis and intestinal villous atrophy]]></article-title>
<source><![CDATA[Scand J Gastroenterol]]></source>
<year>1982</year>
<volume>17</volume>
<page-range>625-8</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lofgren]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jarnerot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Danielsson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hemdal]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden]]></article-title>
<source><![CDATA[Scand J Gastroenterol]]></source>
<year>1985</year>
<volume>20</volume>
<page-range>647-50</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sjoberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lindgren]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Frequent occurrence of non-specific gliadin antibodies in chronic liver disease: Endomysial but not gliadin antibodies predict coeliac disease in patients with chronic liver disease]]></article-title>
<source><![CDATA[Scand J Gastroenterol]]></source>
<year>1997</year>
<volume>32</volume>
<page-range>1162-7</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dickey]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[McMillan]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Callender]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High prevalence of celiac sprue among patients with primary biliary cirrhosis]]></article-title>
<source><![CDATA[J Clin Gastroenterol]]></source>
<year>1997</year>
<volume>25</volume>
<page-range>328-9</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bardella]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Quatrini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zuin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Podda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cesarini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Velio]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Screening patients with celiac disease for primary biliary cirrhosis and viceversa]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>1997</year>
<volume>92</volume>
<page-range>1524-6</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kingham]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The association between primary biliary cirrhosis and coeliac disease: A study of relative prevalences]]></article-title>
<source><![CDATA[Gut]]></source>
<year>1998</year>
<volume>42</volume>
<page-range>120-2</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Niveloni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dezi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pedreira]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Podesta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cabanne]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vázquez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gluten sensitivity in patients with primary biliary cirrhosis]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>1998</year>
<volume>93</volume>
<page-range>404-8</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gillett]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prevalence of celiac disease in collagenous and lymphocytic colitis]]></article-title>
<source><![CDATA[Can J Gastroenterol]]></source>
<year>2000</year>
<volume>14</volume>
<page-range>919-21</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francavilla]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Castellaneta]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hadzic]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mieli Vergani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Coeliac disease in children with autoimmune hepatitis]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2001</year>
<volume>33</volume>
<page-range>624 (abstract)</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[McLoughlin]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Is coeliac disease a potentially treatable cause of liver failure?]]></article-title>
<source><![CDATA[Eur J Gastroenterol Hepatol]]></source>
<year>2005</year>
<volume>17</volume>
<page-range>1015-7</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ojetti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Fini]]></surname>
<given-names><![CDATA[l]]></given-names>
</name>
<name>
<surname><![CDATA[Zileri Dal Verme]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Migneco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pola]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gasbarrini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Acute cryptogenic liver failure in an untreated coeliac patient: A case report]]></article-title>
<source><![CDATA[Eur J Gastroenterol Hepatol]]></source>
<year>2005</year>
<volume>17</volume>
<page-range>1119-21</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pavone]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Guttadauria]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leonardi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Liver transplantation in a child with celiac disease]]></article-title>
<source><![CDATA[J Gastroenterol Hepatol]]></source>
<year>2005</year>
<volume>20</volume>
<page-range>956-60</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
